The Role of Pentraxin 3 and Cathepsin B Levels in Preeclamptic Pregnancy

The Role of Pentraxin 3 and Cathepsin B Levels in the Second Trimester in Predicting of Maternal and Fetal Results in Preeclamptic Pregnancy

In this study, the investigator aim was to compare Cathepsin B and Pentraxin 3 levels measured from maternal serum of pregnant women diagnosed with preeclampsia in the second trimester, the effects of these levels on maternal/ fetal outcomes and the composite results of Cathepsin B and Pentraxin 3 levels alone or together and contribute to the literature in this area.

Study Overview

• Status: Completed
• Conditions: Pre-Eclampsia; Cathepsin B Level; Pentraxin 3 Level
• Intervention / Treatment: Other: Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women

Detailed Description

This prospective case-control study was conducted between 1 January 2022 and 31 December 2022 at Bursa Yuksek Ihtisas Training and Research Hospital. The study was conducted with pregnant women between ages of 18-45 who were diagnosed with preeclampsia in the second trimester. This study was conducted with total 156 pregnant women. participants were grouped according to the presence of preeclampsia; Group1: Patients diagnosed with preeclampsia between 20-28 weeks (study group) (n:78) , Group 2: Healthy pregnant women between 20-28 weeks without a diagnosis of preeclampsia ( control group) (n:78) . As soon as preeclampsia is diagnosed and before any treatment was started, maternal serum samples were collected in the Cathepsin B and Pentraxin 3 kit in amounts suitable for the study. The samples obtained were kept in biochemistry laboratory at -80 degrees until the study was conducted. After all samples were collected, Cathepsin B and Pentraxin 3 values were measured by ELISA method.

• Study Type: Observational
• Enrollment (Actual): 156

Contacts and Locations

Study Locations

• Turkey
  • Bursa, Turkey, 16110
    • Nefise Nazlı YENIGUL

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

singleton pregnancy white people socio-cultural differences were not considered

Description

Inclusion Criteria:

• Singleton pregnancy
• Pregnant women diagnosed with preeclampsia between 20-28 weeks of gestation
• Healthy pregnant women between 20-28 weeks of gestation who want to be involved in the study.

Exclusion Criteria:

• Multiple pregnancies
• Pregnant women who gave birth below 24 weeks of gestation
• Pregnant women diagnosed with other hypertensive diseases of pregnancy other than preeclampsia ( gestational hypertension, chronic hypertension, superimposed hypertension)
• Pregnant women with chromosomal or congenital anomalies in the fetus
• Women with a known infective or autoimmune disease before pregnancy

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Pregnant women with preeclampsia between 20-28 weeks (study group); Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks pregnant women with preeclampsia	Other: Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women; The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia
Healthy pregnant women between 20-28 weeks ( control group); Maternal serum cathepsin B and pentraxin 3 levels in 20-28 weeks healthy pregnant women ( control group)	Other: Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women; The effect of cathepsin b and pentraxin 3 levels on maternal/fetal outcomes in pregnant women diagnosed with preeclampsia

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of the effects and composite results of cathepsin b and pentraxin 3 levels in pregnant women diagnosed with preeclampsia	serum cathepsin b (nmoL pNA/mL) and serum pentraxin 3 (ng/ml) levels composite results on pregnant women diagnosed with preeclampsia	12 months

Collaborators and Investigators

• Sponsor: Sanliurfa Mehmet Akif Inan Education and Research Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2022
• Primary Completion (Actual): December 31, 2022
• Study Completion (Actual): December 31, 2022

Study Registration Dates

• First Submitted: April 4, 2023
• First Submitted That Met QC Criteria: June 19, 2023
• First Posted (Actual): June 29, 2023

Study Record Updates

• Last Update Posted (Actual): June 29, 2023
• Last Update Submitted That Met QC Criteria: June 19, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: preeclampsia; second trimester; Cathepsin B; pentraxin 3
• Additional Relevant MeSH Terms: Pregnancy Complications; Hypertension, Pregnancy-Induced; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Eclampsia; Pre-Eclampsia
• Other Study ID Numbers: 2011-KAEK-25 2021/09-09

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No